Solara Active Pharma Sciences Limited — Q2FY27 earnings call summary

Filed 23 October 2026 · Official transcript

Q2 FY27 revenue grew 33% y-y to INR418 Cr; EBITDA doubled to INR77 Cr (+118% y-y); PAT INR28.5 Cr vs loss last year
Filed 2 DMFs in FY27 so far; targeting 5 total this year
Gross margin for base business ~50% impacted by raw material costs; Ibuprofen gross margin recovered to 36%
Strategic review of Ibuprofen business ongoing; decision expected in 12 weeks
Management focused on operational excellence, capacity debottlenecking, and cash generation
Base business revenue up 37% y-y to INR327 Cr; EBITDA margin expanded 440 bps to 23.6%
Ibuprofen revenue grew 21% y-y; EBITDA loss narrowed to near breakeven
Net debt reduced to ~INR500 Cr; net debt/EBITDA improved to 1.8x from 3.2x